Physician profile
Taz J Harmon
NPI 1629074950
$3,234.68
in general payments reported to CMS, 2019-2025
38 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $754 · 2020: $357 · 2021: $758 · 2022: $723 · 2023: $643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $643.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $643.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $603.96 | 2019-2023 | Erleada |
| Astellas Pharma US INC | $538.19 | 2019-2023 | Myrbetriq |
| Dendreon Pharmaceuticals LLC | $195.64 | 2019-2021 | |
| Pfizer INC. | $176.24 | 2019-2023 | |
| Convatec INC. | $149.52 | 2020-2023 | |
| Caldera Medical, INC | $127.40 | 2023 | Desara |
| Merck Sharp & Dohme LLC | $117.59 | 2021-2022 | |
| Myovant Sciences INC. | $115.66 | 2021-2022 | |
| Amgen INC. | $112.17 | 2019-2021 | |
| Blue Earth Diagnostics | $86.02 | 2019-2023 | |
| Travere Therapeutics, INC. | $83.42 | 2019-2022 | |
| Urovant Sciences INC | $79.18 | 2022 | |
| Boston Scientific Corporation | $76.04 | 2019-2023 | Rezum Generator |
| Abbvie INC. | $71.62 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $69.85 | 2019-2023 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $65.15 | 2019-2021 | |
| Tolmar Pharmaceuticals, INC. | $50.41 | 2019-2022 | |
| Genzyme Corporation | $45.71 | 2019-2020 | |
| Cook Medical LLC | $43.93 | 2019 | |
| Alnylam Pharmaceuticals INC. | $36.92 | 2021 | |
| Baxter Healthcare | $35.11 | 2023 | Tisseel |
| Rochester Medical Corporation | $32.67 | 2022 | |
| Laborie Medical Technologies Corp. | $32.51 | 2023 | |
| Endo Pharmaceuticals INC. | $32.24 | 2021-2023 | Xiaflex |
| Progenics Pharmaceuticals, INC. | $31.99 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.44 | 2021-2022 | |
| Axonics, INC. | $24.31 | 2020 | |
| Accord Healthcare, INC. | $18.65 | 2023 | |
| Telix Pharmaceuticals | $18.45 | 2023 | Illuccix |
| Neotract INC. | $18.20 | 2019 | |
| Sun Pharmaceutical Industries INC. | $17.30 | 2021 | |
| Tolmar, INC. | $15.31 | 2023 | |
| Teleflex LLC | $15.18 | 2022 | |
| Halozyme INC | $14.88 | 2023 | |
| Zyla Life Sciences, INC. | $14.00 | 2020 | |
| Dentsply Ih INC. | $13.67 | 2020 | |
| Clarus Therapeutics INC. | $13.43 | 2021 | |
| Allergan, INC. | $11.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taz Harmon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.